Amorchem
VC Fund
Montréal, Canada
Amorchem is a VC fund in Montréal focused on Biotechnology and Health Care. AmorChem l.p., our fourth focused fund, was launched in 2011 to increase the commercial potential of the quality academic research carried out in Quebec. AmorChem is focused on investing in promising life science projects originating from Québec-based universities and research centres. AmorChem’s innovative business model involves financingresearch-stage projects to enable them to reach pre-clinical proof-of-concept in a semi-virtual mode. AmorChem will generate returns through a two-pronged exit strategy:
- Total investments:
- 6
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Amorchem invests in
Stages Amorchem invests in
Countries Amorchem invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Investment Focus
Industry
- Biotechnology 4 (67%)
- Health Care 3 (50%)
- Biopharma 2 (33%)
- Pharmaceutical 2 (33%)
- Medical 1 (17%)
Stage
- Seed 2 (33%)
- Series A 1 (17%)
- Series B 1 (17%)
- Series C 1 (17%)
- Funding Round 1 (17%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Elizabeth Douville
Founder & Partner
|
Founder & Partner | Total investments: 5 | Find email | |
Kevin McBride
Partner and CSO
|
Partner and CSO | Total investments: 0 | Find email | |
Maxime Pesant
CFO & Partner
|
CFO & Partner | Total investments: 3 | Find email | |
Maxime Ranger
General Partner
|
General Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Inversago Pharma
|
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. | $69.3M / Series C / Oct 17, 2022 | |
Giiant Pharma
|
Giiant is a preclinical-stage biotech company that, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerabilityand enhanced therapeutic effect. | $12.4M / Seed / May 21, 2021 | |
|
Inversago Pharma
|
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. | $35M / Series B / Sep 08, 2020 | |
|
Inversago Pharma
|
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. | $7M / Series A / Jul 25, 2018 | |
Semathera
|
SemaThera is a spin-off company from AmorChem Venture Fund 1, focusing on SEMA 3A protein inhibitor in the treatment of ocular diseases, such as diabetic macular edema. This technology emerges from the laboratory of Dr Mike Sapieha, Hôpital Maisonneuve-Rosement (Montreal, Canada). | $2.6M / Mar 26, 2018 | |
SpecificiT Pharma
|
SpecificiT Pharma Inc., a privately held biopharmaceutical company focused on developing innovative personalized cancer immunotherapies.SpecificiT is developing cellular therapies for hematological cancers which to date, cannot be treated with chimeric antigen receptor modified T cells (CAR-T) therapies.SpecificiT’s unique approach iscentered on the use of Minor Histocompatability Antigens (“MiHAs”) which enable donor T-cells to be safely directed to eliminate cancer cells in a patient. | Seed / Sep 11, 2017 |
Co-Investors
Forbion Capital Partners
5 deals together
Genesys Capital
4 deals together
AQC Capital
3 deals together
Fonds de solidarité FTQ
3 deals together
JDRF T1D Fund
3 deals together
Accel-Rx Health Sciences Accelerator
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Amorchem invest in?
Amorchem invests primarily in Biotechnology, Health Care and Biopharma startups, most often at Seed and Series A stage. Most of the 6 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Amorchem?
Public channels for Amorchem include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Amorchem?
The team at Amorchem includes Elizabeth Douville (Founder & Partner), Kevin McBride (Partner and CSO) and Maxime Pesant (CFO & Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
